BE624917A - - Google Patents
Info
- Publication number
- BE624917A BE624917A BE624917DA BE624917A BE 624917 A BE624917 A BE 624917A BE 624917D A BE624917D A BE 624917DA BE 624917 A BE624917 A BE 624917A
- Authority
- BE
- Belgium
- Prior art keywords
- desc
- composition according
- page number
- active compound
- clms page
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims description 6
- 230000000844 anti-bacterial Effects 0.000 claims description 4
- 150000001412 amines Chemical class 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 230000003000 nontoxic Effects 0.000 claims description 2
- 231100000252 nontoxic Toxicity 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 4
- 241001527806 Iti Species 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 125000004432 carbon atoms Chemical group C* 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000003599 detergent Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 244000052616 bacterial pathogens Species 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000003115 biocidal Effects 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 4
- 230000002421 anti-septic Effects 0.000 description 4
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 3
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 3
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 3
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 3
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 3
- 210000004915 Pus Anatomy 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 241000191940 Staphylococcus Species 0.000 description 3
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 230000000968 intestinal Effects 0.000 description 3
- 229940079866 intestinal antibiotics Drugs 0.000 description 3
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 3
- 230000036269 ulceration Effects 0.000 description 3
- 229940063953 AMMONIUM LAURYL SULFATE Drugs 0.000 description 2
- 206010000496 Acne Diseases 0.000 description 2
- BTBJBAZGXNKLQC-UHFFFAOYSA-N Ammonium lauryl sulfate Chemical compound [NH4+].CCCCCCCCCCCCOS([O-])(=O)=O BTBJBAZGXNKLQC-UHFFFAOYSA-N 0.000 description 2
- 206010009887 Colitis Diseases 0.000 description 2
- 206010013554 Diverticulum Diseases 0.000 description 2
- 241000792859 Enema Species 0.000 description 2
- 210000004907 Glands Anatomy 0.000 description 2
- 229940093912 Gynecological Sulfonamides Drugs 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010033733 Papule Diseases 0.000 description 2
- 206010037888 Rash pustular Diseases 0.000 description 2
- 210000003491 Skin Anatomy 0.000 description 2
- 206010046914 Vaginal infection Diseases 0.000 description 2
- 210000000436 anus Anatomy 0.000 description 2
- 230000001580 bacterial Effects 0.000 description 2
- 201000009910 diseases by infectious agent Diseases 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000007920 enema Substances 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 229940079867 intestinal antiinfectives Sulfonamides Drugs 0.000 description 2
- 230000000813 microbial Effects 0.000 description 2
- 229940005938 ophthalmologic antiinfectives Sulfonamides Drugs 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 231100000486 side effect Toxicity 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 229940026752 topical Sulfonamides Drugs 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 201000008100 vaginitis Diseases 0.000 description 2
- 238000009736 wetting Methods 0.000 description 2
- 200000000019 wound Diseases 0.000 description 2
- 206010000269 Abscess Diseases 0.000 description 1
- 208000004881 Amebiasis Diseases 0.000 description 1
- 206010001980 Amoebiasis Diseases 0.000 description 1
- 210000003503 Anal Sacs Anatomy 0.000 description 1
- 206010002153 Anal fissure Diseases 0.000 description 1
- 229940064004 Antiseptic throat preparations Drugs 0.000 description 1
- 241000219495 Betulaceae Species 0.000 description 1
- 241001416152 Bos frontalis Species 0.000 description 1
- 229910019768 CSi Inorganic materials 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013530 Diverticula Diseases 0.000 description 1
- 229940095399 Enema Drugs 0.000 description 1
- 229940079360 Enema for Constipation Drugs 0.000 description 1
- 208000009531 Fissure in Ano Diseases 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 240000005716 Garcinia dulcis Species 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 210000004080 Milk Anatomy 0.000 description 1
- 206010054107 Nodule Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010039083 Rhinitis Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000008742 Seborrheic Dermatitis Diseases 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- 240000003670 Sesamum indicum Species 0.000 description 1
- 206010052058 Sigmoiditis Diseases 0.000 description 1
- 208000006641 Skin Disease Diseases 0.000 description 1
- ZZORFUFYDOWNEF-UHFFFAOYSA-N Sulfadimethoxine Chemical compound COC1=NC(OC)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 ZZORFUFYDOWNEF-UHFFFAOYSA-N 0.000 description 1
- 101700012140 TAB1 Proteins 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 206010044008 Tonsillitis Diseases 0.000 description 1
- 240000008529 Triticum aestivum Species 0.000 description 1
- 208000000143 Urethritis Diseases 0.000 description 1
- 210000003932 Urinary Bladder Anatomy 0.000 description 1
- 241001459538 Ute Species 0.000 description 1
- 229940029983 VITAMINS Drugs 0.000 description 1
- 229940021016 Vitamin IV solution additives Drugs 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000240 adjuvant Effects 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000003868 ammonium compounds Chemical class 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 239000001166 ammonium sulphate Substances 0.000 description 1
- 210000002255 anal canal Anatomy 0.000 description 1
- 201000010188 anus disease Diseases 0.000 description 1
- 238000004500 asepsis Methods 0.000 description 1
- 230000002238 attenuated Effects 0.000 description 1
- 230000000721 bacterilogical Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 231100000160 chronic toxicity Toxicity 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000000249 desinfective Effects 0.000 description 1
- 201000008286 diarrhea Diseases 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- JZKFHQMONDVVNF-UHFFFAOYSA-N dodecyl sulfate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCCCCCCOS(O)(=O)=O JZKFHQMONDVVNF-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drugs Drugs 0.000 description 1
- 230000002183 duodenal Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000029578 entry into host Effects 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 230000002349 favourable Effects 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 230000002496 gastric Effects 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 230000003760 hair shine Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000002008 hemorrhagic Effects 0.000 description 1
- XKUUMWKWUZRRPD-UHFFFAOYSA-N heptan-2-amine;sulfuric acid Chemical compound [O-]S([O-])(=O)=O.CCCCCC(C)[NH3+].CCCCCC(C)[NH3+] XKUUMWKWUZRRPD-UHFFFAOYSA-N 0.000 description 1
- 230000002757 inflammatory Effects 0.000 description 1
- 230000000366 juvenile Effects 0.000 description 1
- 230000003902 lesions Effects 0.000 description 1
- 101700035385 lili Proteins 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000001717 pathogenic Effects 0.000 description 1
- 230000001575 pathological Effects 0.000 description 1
- 125000000612 phthaloyl group Chemical group C(C=1C(C(=O)*)=CC=CC1)(=O)* 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000000717 retained Effects 0.000 description 1
- 238000011012 sanitization Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000002269 spontaneous Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissues Anatomy 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 230000000472 traumatic Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamins Natural products 0.000 description 1
- 235000021307 wheat Nutrition 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE624917A true BE624917A (pt) |
Family
ID=196394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE624917D BE624917A (pt) |
Country Status (1)
| Country | Link |
|---|---|
| BE (1) | BE624917A (pt) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000016624A1 (en) * | 1998-09-23 | 2000-03-30 | Phycogen, Inc. | Safe and effective biofilm inhibitory compounds and health-related uses thereof |
-
0
- BE BE624917D patent/BE624917A/fr unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000016624A1 (en) * | 1998-09-23 | 2000-03-30 | Phycogen, Inc. | Safe and effective biofilm inhibitory compounds and health-related uses thereof |
| US7087661B1 (en) | 1998-09-23 | 2006-08-08 | Cernofina, Llc | Safe and effective biofilm inhibitory compounds and health-related uses thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2841342T3 (es) | Generación de ácido peroxifórmico mediante formiato de alcohol polihídrico | |
| KR101413138B1 (ko) | 환자의 수술 준비에 사용하기 위한 방법 및 조성물 | |
| JP2007262092A (ja) | 改良された有効性を有するトリクロサンスキンウォッシュ | |
| US10765707B2 (en) | Honey-based gel composition | |
| WO2003057206A1 (en) | Pyruvate cardioplegia solutions for administration to the heart during cardiopulmonary surgery and methods of use thereof | |
| Niezgoda et al. | Evaluation of Vashe Wound Therapy in the clinical management of patients with chronic wounds | |
| JP6659674B2 (ja) | 泡沫形成組成物、及び活性剤を体腔に送達するための方法 | |
| EP2819666B1 (fr) | Formulation gelifiante a base de gluconate de calcium | |
| BE624917A (pt) | ||
| US6322820B1 (en) | Composition of matter and method for the relief of hemorrhoidal conditions | |
| JP6417774B2 (ja) | ソフトコンタクトレンズケア用品 | |
| KR102337124B1 (ko) | 탈모 개선용 복합 파우더 및 이를 포함하는 모발용 화장료 조성물 | |
| EP2285425B1 (fr) | Composition pour la desinfection et la decontamination de corps contamines par des prions ainsi que par des agents transmissibles conventionnels | |
| WO2009057835A1 (en) | Acidic antibiotic composition containing peracid and acetyl salicylic acid | |
| CN102697786A (zh) | 一种乌洛托品复方皮肤消毒液及其制备方法 | |
| CN104206414A (zh) | 用于清洗红光治疗仪的消毒液及其制备方法 | |
| KR20210008251A (ko) | 보습 작용과 살균 작용을 동시에 가지는 무에탄올 손 소독제 및 그 제조방법 | |
| CN103230386A (zh) | 一种免洗皮肤手微乳消毒液制剂及其制备方法 | |
| CN1092050C (zh) | 混合型聚维酮碘消毒剂及其制备方法 | |
| JP2005247779A (ja) | ティートリーを含有するエタノール組成物 | |
| AU2006246966B2 (en) | Method and composition for use in preparation of a patient for surgery | |
| WO2009147328A2 (fr) | Composition pour la désinfection et la décontamination simultanées de corps contaminés par des agents transmissibles conventionnels (atc) et non conventionnels (atnc) | |
| JPS60172921A (ja) | 胆石溶解剤 | |
| JP2008174513A (ja) | プロタミン及びホウ酸含有防腐剤 |